Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Why is tivicay so expensive?

See the DrugPatentWatch profile for tivicay

Short answer:
TIVICAY (glecaprevir/pibrentasvir) is pricey because it was developed to cure hepatitis C with a single, highly effective pill, and the company invested a lot of money and time into research, clinical trials, manufacturing, and marketing. The drug is still under patent protection, so there’s no generic competition yet, and each course costs tens of thousands of dollars—though many insurers and patient‑assistance programs help offset that.


1. Why the price feels high

Factor How it drives the cost
Research & Development (R&D) Developing a new antiviral requires years of basic science, pre‑clinical work, and at least 4‑5 years of clinical trials. Those costs (often > $1 billion) are recouped through the drug’s price.
Patent protection & market exclusivity Gilead holds patents that prevent generics for several years. Without competition, the company can set a higher price.
Single‑pill, single‑course therapy TIVICAY is a once‑daily, 12‑week regimen that can cure most genotypes. The convenience translates into a “premium” price for a “one‑stop” cure.
High manufacturing complexity Both glecaprevir and pibrentasvir are small‑molecule antivirals with specific stability and formulation requirements, driving up production costs.
Regulatory and post‑marketing obligations Meeting FDA/EMA standards and monitoring rare side effects add overhead that is factored into the price.
High treatment value One cure eliminates the need for long‑term monitoring, treatment of complications, and future healthcare costs—making the drug “high‑value” to payers.

2. How the cost is structured

  • Per‑course price – Roughly $90–$100 k in the U.S. for a 12‑week course.
  • Insurance/Medicare coverage – Most commercial plans and Medicare Part D cover it, often with a copay or coinsurance that’s a fraction of the wholesale price.
  • Patient‑assistance programs – Gilead offers a TIVICAY Patient Assistance Program (PAP) for uninsured or under‑insured patients who qualify.
  • Discounts & rebates – Pharmacy benefit managers (PBMs) and insurers negotiate rebates that lower the actual cost paid by payers.

3. What to do if the cost is a concern

Step What to do Why it matters
Ask your prescriber They can check if the drug is needed in your specific case and whether a lower‑cost alternative is available.
Check insurance coverage Call your pharmacy or insurer’s member services to confirm copay, coinsurance, or formulary tier.
Speak with the pharmacist Pharmacists can verify if you qualify for the PAP or for discount cards (e.g., GoodRx, WellRx).
Apply for the PAP Provide medical records and proof of income; the program often covers the full cost for qualifying patients.
Explore manufacturer discounts Some manufacturers offer “co‑pay cards” that reduce your out‑of‑pocket expense.
Look for clinical trials In rare cases, patients may be eligible to receive TIVICAY free of charge as part of a trial.
Ask about generic future Although none exist yet, generics can appear once patents expire (usually 5–10 years after launch).

4. Bottom line

TIVICAY’s high list price reflects the huge upfront cost of drug discovery, the premium of a single, highly effective cure, and the fact that no generic competition exists yet. Most patients don’t pay that full amount—insurance, rebates, and patient‑assistance programs dramatically lower the cost. If you’re concerned, talk to your prescriber, pharmacist, and insurance company; there are usually options to make the drug affordable.



Other Questions About Tivicay :

Tivicay preis? Does medicare cover tivicay? Tivicay 10 mg? Buy tivicay? Tivicay tablets 50mg? Tivicay 50 mg price? Tivicay fda approval date?